Replies to post #207904 on Biotech Values

[biomaven0]

It was two patents denied review - 8,609,646 and 8,466,172

The hepcidin patent likely serves to block AKBA in US as well given any FDA label would talk about use for epo-resistant patients with high hepcidin.

Surviving this review bodes very well for chances of these patents surviving given lower standards of proof and broader claim construction here.